Shijiazhuang Pharma Group Innovation Pharmaceutical Co., Ltd. 2025 Annual Report Summary Securities Code: 300765 Securities Abbreviation: Xin Nuo Wei Announcement No.: 2026-018 Shijiazhuang Pharma Group Innovation Pharmaceutical Co., Ltd. 2025 Annual Report Summary
I. Important Notes This annual report summary is derived from the full annual report. To fully understand the company's operating results, financial status, and future development plans, investors should carefully read the full annual report on the designated media of the China Securities Regulatory Commission. All directors attended the board meeting that reviewed this report. The audit opinion of Deloitte Touche Tohmatsu Certified Public Accountants LLP on the company's financial report for the year was: Standard unqualified opinion. Notes on non-standard audit opinions □ Applicable Not applicable The company was not profitable at the time of listing and is not yet profitable. □ Applicable Not applicable The profit distribution plan or capital reserve to share capital increase plan reviewed by the board of directors for the reporting period □ Applicable Not applicable The company plans to not distribute cash dividends, issue bonus shares, or convert capital reserves into share capital. The profit distribution plan for preferred shares reviewed by the board of directors for the reporting period □ Applicable Not applicable
II. Company Basic Information
-
Company Profile Stock Abbreviation: Xin Nuo Wei Stock Exchange: Shenzhen Stock Exchange Stock Code: 300765 Contact Person and Contact Information Name: Xu Wen, Secretary of the Board: Xu Wen, Securities Affairs Representative: Xu Wen Office Address: Zhang Ju Road, Luancheng District, Shijiazhuang City, Hebei Province, 62 Fax: 0311-67809843 Email: 300765@mail.ecspc.com Zhang Ju Road, Luancheng District, Shijiazhuang City, Hebei Province, 62 Fax: 0311-67809843 Email: 300765@mail.ecspc.com
-
Brief Introduction of Main Business or Products for the Reporting Period (1) Main Business of the Company The company focuses on the research and development, production, and commercialization of biopharmaceuticals, functional raw materials, and health foods. Relying on a large-scale, standardized production system and strict quality control system, the company continuously consolidates its competitive advantage in the global functional raw materials market. At the same time, it accelerates its transformation into an innovative biopharmaceutical enterprise, focusing on cutting-edge technology platforms such as antibody drugs, ADC, and mRNA vaccines, and steadily advancing the research and development and industrialization of its biopharmaceutical pipeline. During the reporting period, the company strictly followed relevant laws and regulations and regulatory requirements, focused on the development of its core business, and steadily advanced various operational tasks. The business situation of the company during the reporting period is detailed below: 1